Evidence map›Paper›PMID 30327187›Full record

Observational studySurgery2019

Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.

Mustapha El Lakis, Andreas Giannakou, Pavel J Nockel, Douglas Wiseman, Sudheer Kumar Gara, Dhaval Patel, Zahraa Abdul Sater, Yevgeniya Y Kushchayeva, Joanna Klubo-Gwiezdzinska, Naris Nilubol and 2 more

Open access · greenAbstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Whole Genome Sequencing PrioritizesFrontiers in endocrinology · 2021
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Mustapha El LakisEndocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Andreas GiannakouNational Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Pavel J NockelEndocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Douglas WisemanEndocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Sudheer Kumar GaraEndocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Dhaval PatelEndocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Zahraa Abdul SaterDiabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Yevgeniya Y KushchayevaDiabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Joanna Klubo-GwiezdzinskaMetabolic Disease Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Naris NilubolEndocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Maria J MerinoLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Electron KebebewEndocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Stanford University, School of Medicine, Stanford, California. Electronic address: kebebew@stanford.edu.
National Institutes of Health · USNational Cancer Institute · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USNational Institute of Diabetes and Digestive and Kidney Diseases · USStanford University · US

Funding

Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NILUBOL, NARIS · 2010 to 2025
$16.6M
Studies of Benign and Malignant Thyroid DiseaseZIEDK047053 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KLUBO-GWIEZDZINSKA, JOANNA · 2013 to 2020
$1.9M
Intramural NIH HHS Z99 DK999999
6 · The paper itself

Abstract

backgroundThere are conflicting reports on whether familial nonmedullary thyroid cancer is more aggressive than sporadic nonmedullary thyroid cancer. Our aim was to determine if the clinical and pathologic characteristics of familial nonmedullary thyroid cancer are different than nonmedullary thyroid cancer.

methodsWe compared patients with familial nonmedullary thyroid cancer to a cohort of 53,571 nonmedullary thyroid cancer patients from the Surveillance, Epidemiology, and End Results database.

resultsA total of 78 patients with familial nonmedullary thyroid cancer from 31 kindreds presented at a younger age (P = .04) and had a greater rate of T1 disease (P = .019), lymph node metastasis (P = .002), and the classic variant of papillary thyroid cancer on histology (P < .001) compared with the Surveillance, Epidemiology, and End Results cohort. Patients with ≥3 affected family members presented at a younger age (P = .04), had a lesser female-to-male ratio (P = .04), and had a greater rate of lymph node metastasis (P = .009). Compared with the Surveillance, Epidemiology, and End Results cohort, we found a higher prevalence of lymph node metastasis in familial nonmedullary thyroid cancer index cases (P = .003) but not in those diagnosed by screening ultrasonography (P = .58).

conclusionPatients with familial nonmedullary thyroid cancer present at a younger age and have a greater rate of lymph node metastasis. The treatment for familial nonmedullary thyroid cancer should be more aggressive in patients who present clinically and in those who have ≥3 first-degree relatives affected.

Indexed as

AdultAge DistributionCarcinoma, MedullaryCohort StudiesFemaleHumansLymphatic MetastasisMaleMiddle AgedMultiple Endocrine Neoplasia Type 2aNeck DissectionSEER ProgramSex DistributionThyroid Cancer, PapillaryThyroidectomyThyroid Neoplasms

Identifiers

PMID30327187
PMCPMC6721606
OpenAlexW2897783472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.